The Technical Analyst
Phio Pharmaceuticals Corp [PHIO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Phio Pharmaceuticals Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.58% $0.638
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.93 mill |
| EPS: | -5.20 |
| P/E: | -0.120 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 4.59 mill |
| Avg Daily Volume: | 0.322 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.120 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.533 - 0.743 ( +/- 16.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Kontulis Caitlin | Sell | 335 | Common stock, $0.0001 par value |
| 2024-02-26 | Bitterman Robert J | Buy | 2 500 | Common stock, $0.0001 par value |
| 2024-02-20 | Bitterman Robert J | Sell | 1 804 | Common stock, $0.0001 par value |
| 2024-02-15 | Kontulis Caitlin | Sell | 658 | Common stock, $0.0001 par value |
| 2024-02-17 | Kontulis Caitlin | Sell | 523 | Common stock, $0.0001 par value |
| INSIDER POWER |
|---|
| 77.74 |
| Last 97 transactions |
| Buy: 3 139 429 | Sell: 140 691 |
Forecast:
16:00 - $0.638
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.638
Forecast 2: 16:00 - $0.638
Forecast 3: 16:00 - $0.638
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.638 (-0.58% ) |
| Volume | 0.0617 mill |
| Avg. Vol. | 0.322 mill |
| % of Avg. Vol | 19.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Latest Press Releases
2024-04-16 07:30:00 - Press Release
Phio Pharmaceuticals Announces Upcoming Presentations At The 81st Annual Meeting Of The Society For Investigative Dermatology (sid)
Phio's lead clinical product candidate, ph-762, is the subject of three new dermatological posters phio's lead clinical product candidate, ph-762, is the subject of three new dermatological posters
2024-04-11 07:30:00 - Press Release
Phio Pharmaceuticals Announces Upcoming Presentation At The 27th Annual Meeting Of The American Society Of Cell And Gene Therapy (ascgt)
Marlborough, mass., april 11, 2024 (globe newswire) -- phio pharmaceuticals corp. (nasdaq: phio), a clinical stage biotechnology company whose proprietary intasyl™ sirna gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, ph-762, an intasyl compound.
2024-04-03 07:30:00 - Press Release
National Spotlight Features Phio's Innovative Rnai Technology Platform
—program will be airing on pbs with dennis quaid in april —it will also be seen on fox business network marlborough, mass., april 03, 2024 (globe newswire) -- phio pharmaceuticals corp. (nasdaq: phio), a clinical stage biotechnology company whose proprietary intasyl™ sirna gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced its intasyl platform will be the focus of viewpoint, a national program hosted by dennis quaid.
2024-04-02 07:30:00 - Press Release
Phio Pharmaceuticals Reports 2023 Year End Financial Results And Provides Business Update
– four sites across the country participating in clinical trial for lead product candidate ph-762 – two patients have already completed treatment – new patent granted for skin related treatments, extending phio's expertise in dermatological treatments for skin care and skin cancer marlborough, mass., april 02, 2024 (globe newswire) -- phio pharmaceuticals corp. (nasdaq: phio), a clinical stage biotechnology company whose proprietary intasyl™ rnai platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the year ended december 31, 2023 and provided a business update.
2024-03-13 14:00:00 - Press Release
Phio Pharmaceuticals Announces Addition Of Clinical Trial Sites At Banner Md Anderson Cancer Center, The George Washington University, And Integrity Research
Marlborough, mass., march 13, 2024 (globe newswire) -- phio pharmaceuticals corp. (nasdaq: phio), a clinical stage biotechnology company whose proprietary intasyl™ sirna gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the addition of three clinical trial sites for its phase 1b study of ph-762: the george washington university—medical faculty associates in washington, d.c.
Latest News
2023-12-05 17:10:33 - PennyStocks
Penny Stocks To Buy Now? 5 Under $5 To Watch This Week
Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it's understandable why penny stocks attract interest from new traders.
2023-10-12 12:47:37 - Zacks Investment Research
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
2023-10-12 08:39:37 - InvestorPlace
Why Is Phio Pharma (PHIO) Stock Down 35% Today?
Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterday. Investors will note that the company's stock saw a 91.2% price increase during normal trading hours on Wednesday.
2023-05-17 12:47:56 - Zacks Investment Research
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
2023-04-18 14:24:40 - InvestorPlace
Why Is PHIO Stock Down 20% Today?
It's been a big day for investors in Phio Pharmaceuticals (NASDAQ: PHIO ), unfortunately on the downside. This afternoon, PHIO stock has declined nearly 20% on a couple of key announcements.
2022-11-10 19:33:07 - Zacks Investment Research
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-25 13:32:36 - Zacks Investment Research
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
Phio Pharmaceuticals Corp. (PHIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-04-18 09:30:00 - PRNewsWire
Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer
MARLBOROUGH, Mass. , April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that in vivo data showing PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response was selected for an encore presentation at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop, which is being held April 21 st – 22nd in San Diego and virtually.
2022-04-08 17:53:09 - PennyStocks
3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes
Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-08 14:19:03 - Benzinga
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) The preclinical data exhibited that PH-894 inhibits tumor growth in both PD-1 inhibition responsive and PD-1.